Risk factors associated with treatment-resistant schizophrenia in first-episode psychosis
DOI:
https://doi.org/10.25118/2236-918X-7-4-1Keywords:
First-episode psychosis, treatmentresistant schizophrenia, risk factorsAbstract
Objective: The risk factors for treatment-resistant schizophrenia (TRS) in first-episode psychosis (FEP) remain unclear. The aim of this study was to investigate risk indicators for TRS in FEP. Methods: A total of 53 patients with FEP and a diagnosis of schizophrenia were selected among individuals seen at the psychiatric ward of Hospital das Clínicas Luzia de Pinho Melo between 2011 and 2015. Upon admission, subjects were evaluated with the Positive and Negative Syndrome Scale (PANSS) and received initial treatment for 4 weeks. Patients showing < 40% reduction on PANSS in response to antipsychotic treatment had the drug changed, and the scales were applied again after 4 weeks. After failure with two antipsychotics, at full doses, for 4 weeks each, clozapine was introduced, and the patient was considered to have TRS. Logistic regression was performed including gender, age at onset, duration of untreated psychosis, substance use, global assessment of functioning at baseline and total PANSS at baseline as independent variables, and TRS as the dependent variable. Results: Duration of untreated psychosis presented significance at p = 0.038 and Exp (B) = 4.29; for total PANSS, results were p = 0.012 and Exp (B) = 1.06. Conclusion: Identifying factors associated with early resistance to treatment could allow clinicians to avoid delays in the introduction of clozapine and prevent worse prognosis for these patients.
Downloads
Metrics
References
Freitas PHB de, Pinto JAF, Sousa PHA de, Enes CL, Machado RM, Nunes FDD. Síndrome metabólica em pacientes com esquizofrenia refrataria:característi cas sociodemográfi case clínicas. Rev Enferm Cent Oeste Min. 2016;6:1976-93.
Kennedy JL, Altar CA, Taylor DL, Degti ar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systemati c literature review. Int Clin Psychopharmacol. 2014;29:63-76.
World Health Organizati on. Global health risks: mortality and burden of disease att ributable to selected major risks. Geneva: WHO; 2009.
Bogers JP, Schulte PF, Van Dijk D, Bakker B, Cohen D. Clozapine underuti lizati on in the treatment of schizophrenia: how can clozapine prescripti on rates be improved? J Clin Psychopharmacol. 2016;36:109-11.
Silveira ASA, Rocha DMLV, Att ux CRF, Dalti o CS, Silva LA, Elkis H, et al. Patt erns of clozapine and other anti psychoti cs prescripti ons in pati ents with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil. Arch Clin Psychiatry (São Paulo). 2015;42:165-70.
Mochcovitch MD, Baczynski TP, Chagas MHC, Papelbaum M, Silva AG, Hallak JEC, et al. Primeiro episódio psicóti co (PEP): diagnósti co e diagnósti co diferencial. São Paulo: Associação Médica Brasileira; 2012.
Louzã Neto MR. Manejo Clínico do primeiro episódio psicóti co. Rev Bras Psiquiatr. 2000;22:45-6.
Orti z BB, Eden FD, de Souza AS, Teciano CA, de Lima DM, Noto C, et al. New evidence in support of staging approaches in schizophrenia: diff erences in clinical profi les between fi rst episode, early stage, and late stage. Compr Psychiatry. 2017;73:93-6.
Agid O, Arenovich T, Sajeev G, Zipursky RB, Kapur S, Foussias G, et al. An algorithm-based approach to fi rst-episode schizophrenia: response rates over 3 prospecti ve anti psychoti c trials with a retrospecti ve data analysis. J Clin Psychiatry. 2011;72:1439-44.
Lally J, Ajnakina O, Di Forti M, Trott a A, Demjaha A, Kolliakou A, et al. Two disti nct patt erns of treatment resistance: clinical predictors of treatment resistance in fi rst episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231-40.
Holthausen EA, Wiersma D, Sitskoorn MM, Hijman R, Dingemans PM, Schene AH, et al. Schizophrenic patients without neuropsychological deficits: subgroup, disease severity or cognitive compensation? Psychiatry Res. 2002;112:1-11.
Pereira A. Esquizofrenia refratária: uma atualização [projeto]. Belo Horizonte: FHEMIG; 1998.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Arlington: American Psychiatric Publishing; 1994.
First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, Version 2.0). New York:
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261-76.
Guy W; National Institute of Mental Health (U.S.); Psychopharmacology Research Branch; Division of Extramural Research Programs. ECDEU assessment manual for psychopharmacology. Rockville: U.S. Dept. of Health, Education, and Welfare; 1976. p. 218-22.
Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-71.
Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psyquiatry. 2000;177:511-5.
Elkis H, Meltzer HY. [Refractory schizophrenia]. Rev Bras Psquiatr. 2007;29:S41-7.
McMahon RP, Kelly DL, Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology. 2002;26:537-45.
Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry. 1999;60:4-8.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
